Acusphere (ACUS) Stock Analysis & Winston Score

Acusphere is a small pharmaceutical company that makes a drug called Imagify, which is used to help doctors take clearer pictures of the heart. Imagify is an ultrasound contrast agent, meaning it makes heart ultrasound scans easier to read. The company sells primarily to hospitals and cardiology clinics in the United States. Acusphere earns revenue by selling Imagify directly into the U.S. healthcare market, and its 100% gross margin reflects the nature of pharmaceutical product sales once manufacturing costs are covered. The company is very small, with a market cap near zero, meaning it has limited financial resources compared to larger drug makers. The key risk is its dependence on a single product — if hospital adoption of Imagify does not grow, or if a larger competitor captures the ultrasound contrast market, the company has little else to fall back on.